Alfaro-Arnedo, Elvira López, Icíar P. Piñeiro-Hermida, Sergio Canalejo, Marta Gotera, Carolina Sola, Jesús Javier Roncero, Alejandra Peces-Barba, Germán Ruíz-Martínez, Carlos Pichel, José G.
...
Published in
Oncogene
Given the long-term ineffectiveness of current therapies and late-stage diagnoses, lung cancer is a leading cause of malignant diseases. Tumor progression is influenced by cancer cell interactions with the tumor microenvironment (TME). Insulin-like growth factor 1 receptor (IGF1R) was reported to affect the TME; however, the role of IGF1R in lung T...
Meijer, Titia G. Nguyen, Luan Van Hoeck, Arne Sieuwerts, Anieta M. Verkaik, Nicole S. Ladan, Marjolijn M. Ruigrok-Ritstier, Kirsten van Deurzen, Carolien H. M. van de Werken, Harmen J. G. Lips, Esther H.
...
Published in
Oncogene
Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-Polymerase (PARP) inhibitors in breast cancer (BC) patients. However, non-germline BRCA1/2 mutated and homologous recombination repair deficient (HRD) tumors are likely also PARP-inhibitor sensitive. Clinical validity and utility of various HRD biomarkers are under inv...
Kim, Ji Young Cho, Tae-Min Park, Jung Min Park, Soeun Park, Minsu Nam, Kee Dal Ko, Dongmi Seo, Juyeon Kim, Seongjae Jung, Eunsun
...
Published in
Oncogene
Despite recent advances, there remains a significant unmet need for the development of new targeted therapies for triple-negative breast cancer (TNBC). Although the heat shock protein HSP90 is a promising target, previous inhibitors have had issues during development including undesirable induction of the heat shock response (HSR) and off-target ef...
Georgiou, Marina Ntavelou, Panagiota Stokes, William Roy, Rajat Maher, Geoffrey J Stoilova, Tsvetana Choo, Josephine A M Y Rakhit, Callum P Martins, Miguel Ajuh, Paul
...
Published in
Oncogene
Rätze, Max A. K. Koorman, Thijs Sijnesael, Thijmen Bassey-Archibong, Blessing van de Ven, Robert Enserink, Lotte Visser, Daan Jaksani, Sridevi Viciano, Ignacio Bakker, Elvira R. M.
...
Published in
Oncogene
Kerr, Aidan Baxter, Robert C.
Published in
Oncogene
The insulin-like growth factors (IGFs) and their regulatory proteins—IGF receptors and binding proteins—are strongly implicated in cancer progression and modulate cell survival and proliferation, migration, angiogenesis and metastasis. By regulating the bioavailability of the type-1 IGF receptor (IGF1R) ligands, IGF-1 and IGF-2, the IGF binding pro...
Constantin, Theodora A. Greenland, Kyle K. Varela-Carver, Anabel Bevan, Charlotte L.
Published in
Oncogene
Transcriptional deregulation has emerged as a hallmark of several cancer types. In metastatic castration-resistant prostate cancer, a stage in which systemic androgen deprivation therapies fail to show clinical benefit, transcriptional addiction to the androgen receptor is maintained in most patients. This has led to increased efforts to find novel...
Lorenzo-Martín, L. Francisco Menacho-Márquez, Mauricio Fernández-Parejo, Natalia Rodríguez-Fdez, Sonia Pascual, Gloria Abad, Antonio Crespo, Piero Dosil, Mercedes Benitah, Salvador A. Bustelo, Xosé R.
...
Published in
Oncogene
It is known that Rho GTPases control different aspects of the biology of skin stem cells (SSCs). However, little information is available on the role of their upstream regulators under normal and tumorigenic conditions in this process. To address this issue, we have used here mouse models in which the activity of guanosine nucleotide exchange facto...
Odeniyide, Patience Yohe, Marielle E. Pollard, Kai Vaseva, Angelina V. Calizo, Ana Zhang, Lindy Rodriguez, Fausto J. Gross, John M. Allen, Amy N. Wan, Xiaolin
...
Published in
Oncogene
Ehsani, Marzieh Bartsch, Sophie Rasa, Seyed Mohammad Mahdi Dittmann, Jessica Pungsrinont, Thanakorn Neubert, Laura Huettner, Soeren S. Kotolloshi, Roland Schindler, Katrin Ahmad, Aya
...
Published in
Oncogene
Castration-resistant prostate cancer (CRPC) is an aggressive lethal form of prostate cancer (PCa). Atraric acid (AA) not only inhibits the wild-type androgen receptor (AR) but also those AR mutants that confer therapy resistance to other clinically used AR antagonists, indicating a different mode of AR antagonism. AA induces cellular senescence and...
